Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib for Bone Metastasis Prevention in Breast Cancer
NCT00692458Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of odanacatib in breast cancer, sponsored by Merck & Co.. Planned start Sep 2008; status: withdrawn.
02
Drugs
odanacatib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00692458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00692458.